Phase III Study to Evaluate the Efficacy and Safety of AD-209

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 280 participants.

Also called NCT06348576

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 280 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06348576
Other papers using this trial's data
  • Low-Dose TEL/AML/CHTD SPC Versus Standard-Dose TEL in Hypertension: Phase III RCT Hypertension (Dallas, Tex. : 1979), 2026-04 DOI, PubMed 41717679, PMC13001893 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT06348576. Randomized; double masking; primary purpose treatment. Start 2024-05-20 (actual); primary completion 2025-02 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase III Study to Evaluate the Efficacy and Safety of AD-209
Condition
Hypertension,Essential
Intervention (Drug)
AD-209
Intervention (Drug)
AD-2091
Intervention (Drug)
AD-209 Placebo
Intervention (Drug)
AD-2091 Placebo
Lead sponsor
Addpharma Inc. (class: industry)

Record details

Record id
cardio:ct-nct06348576
Content hash
017d18553e1c356e032df7341d6b5cc7720dd1edd6ef777915b7b1697148ef5e